A Proud Member of BIO

    

 

 

 


Investor Relations :: Corporate Governance and Nominating Committee Charter

 

Corporate Governance and Nominating Committee Charter

COMPOSITION
 
  1. Composition. The board of directors (the "Board") of La Jolla Pharmaceutical Company (the "Company") shall appoint and maintain a Corporate Governance and Nominating Committee (the "Committee") composed of at least two independent directors of the Company. The independence of the directors on the Committee shall be determined by the Board in accordance with applicable NASD listing standards. The chairperson of the Committee shall be appointed by the Board.
 
  2. Meetings. The Committee will meet as often as may be deemed necessary or appropriate in its judgment, either in person or telephonically, and at such times and places as the Committee shall determine. The Committee shall report regularly to the full Board with respect to its meetings. The majority of the members of the Committee shall constitute a quorum.
 
  3. Outside Advisors. The Committee shall have the authority to retain such outside advisors and experts as it determines necessary or appropriate to assist it in the full performance of its functions, including the authority, without further authorization from the Board, to retain (and determine the terms of retention), compensate and terminate any search firm used by the Committee to identify director candidates.
 
PURPOSE
 
  The purpose of the Committee shall be to assist the Board to identify qualified individuals to become board members, to determine the composition of the Board and its committees, and to monitor and assess the effectiveness of the Board.
 
RESPONSIBILITIES
 
  In furtherance of its purpose, the Committee shall have the following authority and responsibilities:
 
  1. Nominations.
 
    (a) Identify, screen and recommend to the full Board candidates for election to the Board.
 
    (b) Review director candidates recommended by stockholders of the Company.
 
    (c) Assist in attracting qualified director candidates to serve on the Board.
 
    (d) Recommend to the Board members to serve on the committees of the Board.
       
    (e) Review from time to time the skills and characteristics required of Board members in the context of the then current constitution of the Board, including such factors as business experience, technology, finance, financial reporting and other areas that would be expected to contribute to an effective Board.
       
    (f) Monitor the independence, both in appearance and in fact, of current directors and nominees.
       
  2. Governance.
 
    (a) Monitor and assess the relationship between the Board and management with respect to the Board's ability to function independently of management.
 
    (b) Review and assess the channels through which the Board receives information and the quality and timeliness of information received, including assessing the needs of the Board and its committees in terms of the frequency and location of meetings, meeting agendas, discussion papers, reports and other information requirements.
 
    (c) Recommend to the Board enhancements and modifications concerning the structure, composition and functioning of the Board and its committees.
       
    (d) Consider, and recommend when appropriate, director education programs that may serve to enhance the functioning of the Board.
       
    (e) Review periodically the succession plans of the Company at the CEO and other executive officer levels.
 
  3. Other.
 
    (a) Review at least annually the adequacy of this Charter and recommend any changes to the Board.
       
    (b) The foregoing enumerated functions should serve as a guide with the understanding that the Committee may carry out additional functions and adopt additional policies and procedures as may be appropriate to serve its purpose in light of changing business, legislative, regulatory, legal or other conditions. The Committee shall also carry out such additional responsibilities and duties delegated to it by the Board from time to time.
       
  Last Updated: February 25, 2004
 

Terms of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company










 

 

 

 

 

 

 

 

 

 

 

 

 

Link to conference call